Cytokinetics, Inc. (CYTK) Tops Q3 EPS by 5c; Guides FY11 Revs Below
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $75.26 -0.5%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.36 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Cytokinetics sues Bristol-Myers Squibb over aficamten patent dispute
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
